Compare Camlin Fine with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with a -12.68% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.61 times
- The company has been able to generate a Return on Equity (avg) of 5.57% signifying low profitability per unit of shareholders funds
Flat results in Dec 25
Below par performance in long term as well as near term
Stock DNA
Specialty Chemicals
INR 2,334 Cr (Small Cap)
1,330.00
37
0.00%
0.58
0.98%
2.59
Total Returns (Price + Dividend) 
Latest dividend: 0.44999999999999996 per share ex-dividend date: Jul-28-2016
Risk Adjusted Returns v/s 
Returns Beta
News

Camlin Fine Sciences Ltd is Rated Strong Sell
Camlin Fine Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with the most up-to-date analysis.
Read full news article
Camlin Fine Sciences Ltd Hits Intraday Low Amidst Price Pressure
Camlin Fine Sciences Ltd, a specialty chemicals company, experienced a significant intraday decline on 19 Mar 2026, touching a new 52-week low of Rs 119.8. The stock underperformed both its sector and the broader market, reflecting persistent downward momentum amid a challenging market environment.
Read full news article
Camlin Fine Sciences Ltd Falls to 52-Week Low Amid Continued Downtrend
Camlin Fine Sciences Ltd, a player in the specialty chemicals sector, has touched a new 52-week low of Rs.123.4 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions.
Read full news article Announcements 
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
18-Mar-2026 | Source : BSEThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 17 2026 for Ashish Subhash Dandekar
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.
18-Mar-2026 | Source : BSEThe Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on March 17 2026 for Ashish Subhash Dandekar
Announcement under Regulation 30 (LODR)-Restructuring
18-Mar-2026 | Source : BSEOpening of judicial liquidation proceedings of CFS Europe S.p.A. a wholly owned subsidiary of the Company.
Corporate Actions 
No Upcoming Board Meetings
Camlin Fine Sciences Ltd has declared 45% dividend, ex-date: 28 Jul 16
Camlin Fine Sciences Ltd has announced 1:2 stock split, ex-date: 04 Sep 14
No Bonus history available
Camlin Fine Sciences Ltd has announced 5:41 rights issue, ex-date: 08 Jan 25
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Nov 2025
Shareholding Compare (%holding) 
Promoters
10.8385
Held by 5 Schemes (7.04%)
Held by 46 FIIs (2.15%)
Ashish Subhash Dandekar (10.3%)
Icici Prudential Commodities Fund (4.03%)
26.89%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is 6.07% vs 11.70% in Dec 2024
YoY Growth in quarter ended Dec 2025 is -775.12% vs 64.89% in Dec 2024
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 10.68% vs -3.31% in Sep 2024
Growth in half year ended Sep 2025 is 81.86% vs -3,403.66% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 9.06% vs 1.47% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 56.21% vs -785.60% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 14.62% vs -13.54% in Mar 2024
YoY Growth in year ended Mar 2025 is -49.92% vs -277.99% in Mar 2024






